Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA Study of FZ-AD005 in Patients With Advanced Solid Tumors
- Where
- Changsha, Hangzhou, Shanghai
- Életkor
- 18 év to 75 év
- People
- 162
- Run by
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
See details and how to joinNCT06424665 - 2. fázisTaking peopleConcurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 47
- Run by
- Sun Yat-sen University
See details and how to joinNCT06719700 - No phaseTaking peopleTo Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
- Where
- Beijing
- Életkor
- 18 év to 85 év
- People
- 100
- Run by
- Peking University People's Hospital
See details and how to joinNCT07291921 - 1. fázisTaking peopleAn Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Shanghai AbelZeta Ltd.
See details and how to joinNCT07444281 - 1. fázisTaking peopleIntrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 19
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT06663306 - 3. fázisTaking peopleAnlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 134
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07443397 - 2. fázisTaking peopleGolidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
- Where
- Beijing, Chongqing
- Életkor
- 18 év and over
- People
- 20
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07110103 - No phaseTaking peopleStudy of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
- Where
- Changchun
- Életkor
- 18 év and over
- People
- 900
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07439991 - 1/2. fázisTaking peopleCarbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Where
- Beijing, Chengdu, Chongqing, Fuzhou, Haikou, Heilongjiang, Henan, Hunan, Shanghai
- Életkor
- 18 év to 80 év
- People
- 54
- Run by
- Sichuan Enray Pharmaceutical Sciences Company
See details and how to joinNCT07433283 - No phaseTaking peopleA Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
- Where
- Shanghai
- Életkor
- 18 év to 100 év
- People
- 500
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07434518 - 2. fázisTaking peopleTislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
- Where
- Chongqing
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Chongqing University Cancer Hospital
See details and how to joinNCT07425795 - 1/2. fázisTaking peopleBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- Where
- Beijing
- Életkor
- 8 év to 85 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT07410494 - 1/2. fázisTaking peopleEBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Where
- Beijing
- People
- 83
- Run by
- Essen Biotech
See details and how to joinNCT07410676 - 1. fázisTaking peopleA Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 24
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT07413042 - 2. fázisNot yet taking people in KínaLimertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 45
- Run by
- The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07413952 - 1/2. fázisNot yet taking people in KínaA Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 48
- Run by
- Shanghai Best-Link Bioscience, LLC
See details and how to joinNCT07414927 - 2. fázisTaking peopleIBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 43
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07408635 - No phaseNot yet taking people in KínaTubeless Strategy for Enhanced Recovery After Sublobar Resection
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 138
- Run by
- The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07409129 - 2. fázisNot yet taking people in KínactDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
- Where
- Shijiazhuang
- Életkor
- 18 év to 75 év
- People
- 84
- Run by
- Hebei Medical University Fourth Hospital
See details and how to joinNCT07410611 - 2. fázisTaking peopleEfficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 54
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07410975 - 2. fázisTaking peopleStudy of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 60
- Run by
- Fudan University
See details and how to joinNCT06943235 - 2. fázisTaking peopleA Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 33
- Run by
- Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07082179 - 2. fázisNot yet taking people in KínaIBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 10
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07402070 - 1/2. fázisTaking peopleStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Where
- Baoding, Beijing, Bengbu, Cangzhou, Ch’ang-ch’un, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Dalian, Fuzhou, Ganzhou, Guangzhou, Ha’erbin, Hangzhou, Hanzhong, Harbin, Hefei, Henan, Hohhot, Jiangxi, Jilin City, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Qinhuangdao, Shanghai, Shantou, Shenyang, Shenzhen, Suzhou, Taiyuan, Taizhou, Tianjin, Tonghua, Weifang, Wenzhou, Wuhan, Wuhu, Xiamen, Xi’an, Xuzhou, Yantai, Yibin, Yinchuan, Zhengzhou, Zhenzhou
- Életkor
- 18 év and over
- People
- 400
- Run by
- Betta Pharmaceuticals Co., Ltd.
See details and how to joinNCT04930432 - No phaseTaking peopleValidation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
- Where
- Guangzhou
- People
- 1000
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07239063